Corteva (NYSE:CTVA) Releases Earnings Results

Corteva (NYSE:CTVA) issued its quarterly earnings data on Thursday. The company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.24 by $0.06, Zacks reports. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The firm had revenue of $6.38 billion during the quarter, compared to the consensus estimate of $6.60 billion. During the same period in the prior year, the firm posted $2.20 earnings per share. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. Corteva updated its FY 2026 guidance to 3.600-3.800 EPS.

Corteva Stock Performance

Shares of NYSE CTVA traded down $1.12 during midday trading on Thursday, hitting $89.39. 5,561,841 shares of the stock traded hands, compared to its average volume of 3,166,264. The firm has a 50-day moving average of $82.16 and a two-hundred day moving average of $79.55. The firm has a market capitalization of $59.79 billion, a P/E ratio of 24.53, a PEG ratio of 2.74 and a beta of 0.56. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.03 and a current ratio of 1.47. Corteva has a one year low of $60.53 and a one year high of $90.97.

Corteva Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st will be issued a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, September 1st. Corteva’s dividend payout ratio is presently 42.35%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CTVA shares. Citigroup increased their target price on Corteva from $83.00 to $85.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. UBS Group reduced their price target on Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 9th. Royal Bank Of Canada increased their price objective on Corteva from $97.00 to $103.00 and gave the stock an “outperform” rating in a report on Tuesday, July 21st. Barclays raised their price objective on Corteva from $84.00 to $91.00 and gave the company an “overweight” rating in a research report on Thursday, June 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Corteva from $90.00 to $100.00 in a report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $90.19.

Institutional Trading of Corteva

A number of hedge funds have recently bought and sold shares of the company. Kelleher Financial Advisors boosted its position in Corteva by 3.8% in the third quarter. Kelleher Financial Advisors now owns 4,594 shares of the company’s stock worth $311,000 after purchasing an additional 170 shares during the last quarter. Binnacle Investments Inc increased its position in shares of Corteva by 54.7% during the 2nd quarter. Binnacle Investments Inc now owns 512 shares of the company’s stock valued at $38,000 after purchasing an additional 181 shares during the last quarter. Cresset Asset Management LLC lifted its stake in shares of Corteva by 2.6% in the 2nd quarter. Cresset Asset Management LLC now owns 7,063 shares of the company’s stock worth $526,000 after purchasing an additional 181 shares during the period. CreativeOne Wealth LLC boosted its holdings in shares of Corteva by 2.6% in the fourth quarter. CreativeOne Wealth LLC now owns 7,699 shares of the company’s stock worth $516,000 after buying an additional 194 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its holdings in shares of Corteva by 1.4% in the fourth quarter. Quadrant Capital Group LLC now owns 14,500 shares of the company’s stock worth $972,000 after buying an additional 198 shares during the last quarter. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva News Summary

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Quarterly earnings exceeded expectations: Corteva reported second-quarter EPS of $2.30, above the $2.24 consensus estimate and up from $2.20 a year earlier. Corteva Q2 Earnings Beat Estimates
• Positive Sentiment: Full-year outlook was raised: Management increased its 2026 EPS guidance to $3.60-$3.80, reflecting strong first-half performance, cost controls and growth from strategic platforms. The midpoint is broadly consistent with analyst expectations. Corteva Delivers Strong First Half and Raises Outlook
• Positive Sentiment: Growth initiatives remain supportive: Demand for newer seed germplasm, trait technologies and crop-protection products, along with licensing growth and operational improvements, helped offset competitive pricing pressure. Corteva also remains on schedule for the planned October 1 Vylor spin-off. Why Corteva’s Seed and Crop Protection Engines Matter
• Neutral Sentiment: Separation could reshape the investment story: Corteva’s innovation pipeline, including crop-protection products and royalty opportunities, may support future growth after the planned business split, although the benefits will depend on execution. Corteva’s Innovation Pipeline
• Negative Sentiment: Revenue missed expectations: Second-quarter revenue was $6.38 billion, below the $6.60 billion analyst estimate, and declined 1.2% year over year. Competitive pricing remains a concern. Corteva Earnings Press Release
• Negative Sentiment: Valuation and execution risks are elevated: After a powerful rally, CTVA trades near its 52-week high at a premium earnings multiple. Investors may remain cautious about separation costs, execution risk and whether growth can justify the valuation. Is CTVA Stock Worth Buying After Its Rally?

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid?2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.